[go: up one dir, main page]

NZ507829A - Vaccine adjuvants for immunotherapy of melanoma - Google Patents

Vaccine adjuvants for immunotherapy of melanoma

Info

Publication number
NZ507829A
NZ507829A NZ507829A NZ50782999A NZ507829A NZ 507829 A NZ507829 A NZ 507829A NZ 507829 A NZ507829 A NZ 507829A NZ 50782999 A NZ50782999 A NZ 50782999A NZ 507829 A NZ507829 A NZ 507829A
Authority
NZ
New Zealand
Prior art keywords
antigen
composition
presenting cells
immunotherapy
melanoma
Prior art date
Application number
NZ507829A
Inventor
Matthew L Sherman
Thomas E Gajewski
Francesca Fallarino
Original Assignee
Arch Dev Corp
Inst Genetics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/064,964 external-priority patent/US6080399A/en
Application filed by Arch Dev Corp, Inst Genetics Llc filed Critical Arch Dev Corp
Publication of NZ507829A publication Critical patent/NZ507829A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Use of IL-12 and antigen-presenting cells pulsed with peptide in the preparation of a medicament for inducing a mammalian immune response, wherein the antigen-presenting cells are not dendritic cells, a method of inducing an immune response in a non-human mammal comprising: a) providing a composition comprising IL-12; b) providing a composition comprising IL-12 and said composition comprising antigen-presenting cells pulsed with peptide to a non-human mammal in an amount effective to induce an immune response, wherein the antigen-presenting cells are not dendritic cells, a method of treating a non-human mammal with a disease comprising administering a composition comprising antigen-presenting cells pulsed with peptide wherein the antigen presenting cells are not dendritic cells and a composition comprising IL-12.
NZ507829A 1998-04-23 1999-04-23 Vaccine adjuvants for immunotherapy of melanoma NZ507829A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/064,964 US6080399A (en) 1998-04-23 1998-04-23 Vaccine adjuvants for immunotherapy of melanoma
US09/168,832 US6716422B1 (en) 1998-04-23 1998-10-08 Vaccine adjuvants for immunotherapy of melanoma
PCT/US1999/008889 WO1999053949A2 (en) 1998-04-23 1999-04-23 Combination of antigen pulsed apcs and interleukin 12 for tumor and viral therapy

Publications (1)

Publication Number Publication Date
NZ507829A true NZ507829A (en) 2004-03-26

Family

ID=26745085

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507829A NZ507829A (en) 1998-04-23 1999-04-23 Vaccine adjuvants for immunotherapy of melanoma

Country Status (6)

Country Link
EP (1) EP1071450A2 (en)
JP (1) JP2002512202A (en)
AU (1) AU767208B2 (en)
CA (1) CA2326406A1 (en)
NZ (1) NZ507829A (en)
WO (1) WO1999053949A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
FR2795074A1 (en) * 1999-05-21 2000-12-22 Inst Nat Sante Rech Med POLYPEPTIDES TRANSPORTING AMINO ACIDS, IN PARTICULAR GLUTAMATE, AND METHODS OF SCREENING INHIBITOR OR ACTIVATOR COMPOUNDS OF TRANSPORT ACTIVITY
DE60218173T2 (en) 2002-10-11 2007-11-22 Sentoclone Ab Immunotherapy for cancer
WO2004069272A2 (en) * 2003-02-05 2004-08-19 Movecare Ltd Adjuvant combination for use in the immunization of a mamal comprising il2 and il12
JP5205275B2 (en) 2005-12-21 2013-06-05 セントクローネ インターナショナル エービー Treatment of sporadic cancer
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
WO2007071388A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
US8101173B2 (en) 2005-12-21 2012-01-24 Sentoclone International Ab Method for treating urinary bladder cancer
WO2009133863A1 (en) * 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Immunopotentiating agent comprising ep1 agonist
CN102046789A (en) * 2008-05-29 2011-05-04 希森美康株式会社 Primer for detection of tyrosinase mRNA
JP2012025694A (en) * 2010-07-23 2012-02-09 Asahi Kasei Kuraray Medical Co Ltd Cancer therapeutic agent
WO2019136305A1 (en) * 2018-01-04 2019-07-11 Neumedicines Inc. Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells

Also Published As

Publication number Publication date
WO1999053949A2 (en) 1999-10-28
CA2326406A1 (en) 1999-10-28
AU767208B2 (en) 2003-11-06
JP2002512202A (en) 2002-04-23
WO1999053949A9 (en) 2000-05-25
EP1071450A2 (en) 2001-01-31
AU3865999A (en) 1999-11-08
WO1999053949A3 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
ES2529257T3 (en) B cell-based vaccine loaded with the natural killer T cell ligand and antigen
ATE432085T1 (en) STIMULATION FACTOR FOR DENDRITES
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
DK1225870T3 (en) Composition and method of cancer antigen immunotherapy
HK1044484B (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
TR200100936T2 (en) Therapeutic vaccination
NO20013875D0 (en) Maturation of dendritic cells with immune response modifying compound
MXPA04003864A (en) Immunotherapy for reversing immune suppression.
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
Golstein et al. Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions
ES2177927T3 (en) COMPOSITION TO CAUSE AN IMMUNOLOGICAL REACTION TO A NON-PROTEIN ANTIGEN DETERMINANT
AU2003296439B2 (en) In situ maturation of dendritic cells
MXPA03010261A (en) Methods for treating cancer.
CA2340786C (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
WO2002053176A3 (en) An autologous anti-cancer vaccine
IL189615A0 (en) Melanoma vaccine and methods of making and using same
OA09863A (en) Use of IL-4 to enhance immune response to immunogens in vaccines.
MY127452A (en) Vaccines.
WO2001080887A3 (en) Methods and chemokin compositions for inducing an immune response
HK1025220A1 (en) Novel saponin compositions and uses thereof
AU5714801A (en) Methods and compositions for eliciting an immune response
RU2420311C2 (en) Vaccine based on b-cells, loaded with ligands of t-cells-natural killers and antigen
MX9800821A (en) ISOLATION AND / OR CONSERVATION OF DENTAL CELLS FOR THE IMMUNOTHERAPY OF CANCER DE LA PROSTATA.
Hamada Therapy of established tumor with a novel tumor vaccine developed by fusion of tumor cells with GM-CSF genetically modified dendritic cells

Legal Events

Date Code Title Description
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: PROPRIETOR NAMES CORRECTED FOR THE FOLLOWING: GENETICS INSTITUTE, INCORPORATED, ARCH DEVELOPMENT CORPORATION

ASS Change of ownership

Owner name: GENETICS INSTITUTE, US

Free format text: OLD OWNER(S): GENETICS INSTITUTE, INCORPORATED; ARCH DEVELOPMENT CORPORATION

Owner name: ARCH DEVELOPMENT CORPORATION, US

Free format text: OLD OWNER(S): GENETICS INSTITUTE, INCORPORATED; ARCH DEVELOPMENT CORPORATION

PSEA Patent sealed
RENW Renewal (renewal fees accepted)